EGFR and neoplasm: However, osimertinib has demonstrated high efficacy in NSCLC patients harboring the T790M resistance mutation detected through ctDNA, even in cases where tumor mutation status is unknown and progression has occurred following prior EGFR-TKI therapy [51].